ABL Bio Inc.

298380· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩80,400+13.24%

2026-08-04

Financials

Valuation Metrics

ABL Bio Inc.'s Market Cap is ₩4.5T. At end of 2025 it was ₩11.2T. Ranked #110 of 2,436 in KR market (top 5%), #9 of 1,649 on KOSDAQ (top 0.5%), #8 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 3%) by Market Cap.

Investment Metrics(as of 2026-08-04)

Metric	Value	Rank
Size
Market Cap	4.50T KRW	KR#110/2,436 Sec#8/234
Revenue	90.32B KRW	KR#1,452/2,436 Sec#91/234
Net Income	-24.39B KRW	KR—/2,436 Sec—/234
Total Assets	298.13B KRW	KR#1,022/2,436 Sec#71/234
Net Assets	183.34B KRW	KR#974/2,436 Sec#68/234
Employees	104	KR#1,600/2,436 Sec#124/234
Value
P/B	24.55x	KR#2,390/2,436 Sec#222/234
P/S	49.84x	KR#2,367/2,436 Sec#196/234
FCF Yield	-0.92%	KR—/2,436 Sec—/234
Profitability
ROE	-13.30%	KR#1,956/2,436 Sec#153/234
ROA	-8.18%	KR#2,016/2,436 Sec#152/234
Op. Margin	-31.64%	KR#2,182/2,436 Sec#154/234
Revenue Growth	506.83%	KR#19/2,436 Sec#3/234
Financial Health
Debt Ratio	62.61%	KR#213/2,436 Sec#30/234
Total Debt	55.00B KRW	KR#947/2,436 Sec#64/234
FCF	-41.38B KRW	KR#2,058/2,436 Sec#204/234
Cash	186.73B KRW	KR#283/2,436 Sec#12/234
Current Ratio	1.70x	KR#1,150/2,436 Sec#126/234
Performance
1Y Return	12.13%	KR#501/2,436 Sec#41/234
1M Return	-16.34%	KR#2,072/2,436 Sec#206/234
From 52W High	-68.78%	KR#2,089/2,436 Sec#184/234
1Y MDD	-75.23%	KR#2,154/2,436 Sec#193/234
Trading
Volume	637,605 shares	KR#214/2,436 Sec#17/234
Foreign Own.	14.52%	KR#319/2,436 Sec#20/234
Per Share
EPS	-439 KRW	KR—/2,436 Sec—/234
BPS	3,226 KRW	KR#1,766/2,436 Sec#134/234

Company Info

CEO 이상훈

Employees 104

Founded 2016

HQ 서울 강남구, KR

Website www.ablbio.com

동사는 2016년 설립돼 2018년 코스닥에 상장한 바이오의약품 연구개발 전문기업임. 이중항체 기술 플랫폼 'Grabody™'로 면역관문 조절, 신규 타깃 발굴, 퇴행성뇌질환 치료제, 항체-약물 접합체 등 항체치료제를 연구개발하고 있음. 경쟁력 있는 플랫폼과 다양한 파이프라인 확보, 기술이전을 통한 외형 확대와 엄격한 의사결정 체계를 적용하여 높은 가치 창출을 추구하고 있음. 에이비엘바이오는 2016년에 설립되었으며 서울 강남구에 본사를 두고 있습니다.